In addition to FBP1 deletion significantly affecting the progression of hepatocellular carcinoma [12] and renal carcinoma [13], it is also down-regulated in gastric [14], pancreatic [15], colorectal [16], breast [17], prostate [18], bile duct [19], esophageal [20], lung [21], and ovarian cancers [22]. Here, FBP1 is linked to hepatocellular carcinoma.